Coherus Oncology is reducing its workforce by 30% as it narrows its pipeline to focus on esophageal cancer. Gyre Therapeutics is also conducting layoffs following its acquisition of Cullgen. These workforce reductions are part of broader organizational restructuring efforts. The companies aim to achieve financial benefits and streamline operations through these changes. Specific numbers for Gyre's layoffs were not disclosed.
San Francisco, California
https://www.biospace.com/job-trends/coherus-cuts-30-of-staffers-gyre-makes-post-acquisition-layoffs